XML 48 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Product Sales (Tables)
 12 Months Ended
Dec. 31, 2018
Revenues [Abstract]  
Schedule of Product Sales
Net product sales consist of the following:
 
 
Year Ended December 31,
Net Product Sales in the United States
 
2018
 
2017
 
2016
EYLEA
 
$
4,076.7

 
$
3,701.9

 
$
3,323.1

Libtayo
 
14.8

 
—

 
—

ARCALYST
 
14.7

 
16.6

 
15.3

 
 
$
4,106.2

 
$
3,718.5

 
$
3,338.4

The collaboration revenue we earned from Sanofi is detailed below:
 
 
Year Ended December 31,
Sanofi Collaboration Revenue
 
2018
 
2017
 
2016
Antibody:
 
 
 
 
 
 
Reimbursement of Regeneron research and development expenses
 
$
265.3

 
$
508.4

 
$
564.9

Reimbursement of Regeneron commercialization-related expenses
 
417.2

 
368.8

 
305.9

Regeneron's share of losses in connection with commercialization of antibodies
 
(227.0
)
 
(442.6
)
 
(459.0
)
Other
 
103.5

 
119.1

 
28.4

Total Antibody
 
559.0

 
553.7

 
440.2

Immuno-oncology:
 
 
 
 
 
 
Reimbursement of Regeneron research and development expenses
 
311.8

 
240.0

 
138.5

Reimbursement of Regeneron commercialization-related expenses
 
8.9

 
7.0

 
—

Other
 
231.4

 
76.5

 
80.0

Total Immuno-oncology
 
552.1

 
323.5

 
218.5

 
 
$
1,111.1

 
$
877.2

 
$
658.7

Revenue earned in connection with our Bayer EYLEA collaboration is as follows (note that the table excludes amounts in connection with our Bayer Ang2 antibody and PDGFR-beta antibody collaboration agreements, which are described below):
 
 
Year Ended December 31,
Bayer EYLEA Collaboration Revenue
 
2018
 
2017
 
2016
Regeneron's net profit in connection with commercialization of EYLEA outside the United States
 
$
992.3

 
$
802.3

 
$
649.2

Reimbursement of Regeneron EYLEA development expenses
 
11.2

 
13.3

 
9.0

Other
 
73.6

 
58.7

 
52.6

 
 
$
1,077.1

 
$
874.3

 
$
710.8
Schedules of Concentration of Risk, by Risk Factor
The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for each of the years ended December 31, 2018, 2017, and 2016. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:
 
Year Ended December 31,
 
2018
 
2017
 
2016
Besse Medical, a subsidiary of AmerisourceBergen Corporation
56
%
 
51
%
 
55
%
McKesson Corporation
36
%
 
29
%
 
28
%
Curascript SD Specialty Distribution, a subsidiary of Express Scripts
**

 
19
%
 
16
%
** Sales to Curascript SD Specialty Distribution represented less than 10% of total gross product revenue during the period.
Sales Related Deductions Activity
The following table summarizes the provisions, and credits/payments, for these sales-related deductions for the years ended December 31, 2018, 2017, and 2016.
 
Rebates, Chargebacks, and Discounts
 
Distribution-
Related
Fees
 
Other Sales-
Related
Deductions
 
Total
Balance as of December 31, 2015
$
6.4

 
$
48.4

 
$
0.5

 
$
55.3

Provisions
93.4

 
154.4

 
30.4

 
278.2

Credits/payments
(87.1
)
 
(173.3
)
 
(27.3
)
 
(287.7
)
Balance as of December 31, 2016
12.7

 
29.5

 
3.6

 
45.8

Provisions
167.8

 
194.1

 
46.4

 
408.3

Credits/payments
(150.6
)
 
(189.5
)
 
(28.7
)
 
(368.8
)
Balance as of December 31, 2017
29.9

 
34.1

 
21.3

 
85.3

Provisions
223.4

 
211.0

 
44.5

 
478.9

Credits/payments
(212.2
)
 
(203.1
)
 
(57.5
)
 
(472.8
)
Balance as of December 31, 2018
$
41.1

 
$
42.0

 
$
8.3

 
$
91.4